BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 8978998)

  • 1. Mycophenolate mofetil in kidney transplantation.
    Lui SL; Halloran PF
    Curr Opin Nephrol Hypertens; 1996 Nov; 5(6):508-13. PubMed ID: 8978998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW
    Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection.
    Simmons WD; Rayhill SC; Sollinger HW
    Drug Saf; 1997 Aug; 17(2):75-92. PubMed ID: 9285199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.
    Fulton B; Markham A
    Drugs; 1996 Feb; 51(2):278-98. PubMed ID: 8808168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation.
    Behrend M
    Clin Nephrol; 1996 May; 45(5):336-41. PubMed ID: 8738667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial.
    Remuzzi G; Lesti M; Gotti E; Ganeva M; Dimitrov BD; Ene-Iordache B; Gherardi G; Donati D; Salvadori M; Sandrini S; Valente U; Segoloni G; Mourad G; Federico S; Rigotti P; Sparacino V; Bosmans JL; Perico N; Ruggenenti P
    Lancet; 2004 Aug 7-13; 364(9433):503-12. PubMed ID: 15302193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of Mycophenolate Mofetil (Cellcept) in renal transplantation.
    Vanrenterghem Y
    Nephron; 1997; 76(4):392-9. PubMed ID: 9274835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate mofetil--is it worth the cost? The in-favor opinion.
    Seikaly MG
    Pediatr Transplant; 1999 Feb; 3(1):79-82. PubMed ID: 10359036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost effectiveness of mycophenolate mofetil in the first year after primary cadaveric transplant. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sullivan SD; Garrison LP; Best JH
    J Am Soc Nephrol; 1997 Oct; 8(10):1592-8. PubMed ID: 9335389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate mofetil for maintenance therapy in kidney transplantation.
    Gonwa TA
    Clin Transplant; 1996 Feb; 10(1 Pt 2):128-30. PubMed ID: 8680049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A placebo controlled study of mycophenolate mofetil used in combination with cyclosporine and corticosteroids for the prevention of acute rejection in renal allograft recipients: 1-year results. The European Mycophenolate Mofetil Cooperative Study Group.
    Wiesel M; Carl S
    J Urol; 1998 Jan; 159(1):28-33. PubMed ID: 9400430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil: suggested guidelines for use in kidney transplantation.
    Behrend M
    BioDrugs; 2001; 15(1):37-53. PubMed ID: 11437674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil.
    Sievers TM; Rossi SJ; Ghobrial RM; Arriola E; Nishimura P; Kawano M; Holt CD
    Pharmacotherapy; 1997; 17(6):1178-97. PubMed ID: 9399601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of mycophenolate mofetil in kidney transplantation].
    Hrvacevic R; Ignjatovic Lj; Vavic N
    Vojnosanit Pregl; 2001; 58(4):415-9. PubMed ID: 11712223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil.
    Wüthrich RP; Weinreich T; Ambühl PM; Schwarzkopf AK; Candinas D; Binswanger U
    Nephrol Dial Transplant; 1999 Feb; 14(2):394-9. PubMed ID: 10069195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mycophenolate mofetil, a possible new immunosuppresant].
    Weberová J; Voboril R; Semecký V
    Ceska Slov Farm; 2002 Sep; 51(5):220-5. PubMed ID: 12407919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients.
    Machnicki G; Ricci JF; Brennan DC; Schnitzler MA
    Pharmacoeconomics; 2008; 26(11):951-67. PubMed ID: 18850764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil for the transplanted kidney?
    Drug Ther Bull; 1997 May; 35(5):38-40. PubMed ID: 9282420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil, along with ATG and cyclosporine, significantly lowers the incidence of acute rejection episodes in renal transplant recipients.
    Puig JM; Lloveras J; Fernández-Crespo P; Mir M; Iñigo V; Manresa JM; Masramón J
    Transplant Proc; 1999 Sep; 31(6):2259-60. PubMed ID: 10500567
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.